Dr. Badros has extensive clinical experience in Bone Marrow Transplantation with special interest in multiple myeloma. He was involved in the initial trails of thalidomide and has conducted many clinical trials for treatment of relapsed and refractory multiple myeloma. Dr. Badros research has focused on evaluation of immunological approaches to eradicate residual myeloma cells in the high-risk setting following autologous stem cell transplantation using natural killer (NK) and interleukin -2 (IL-2) activated cells and non-myeloablative allogeneic donor grafts.
Dr. Badros is involved in the development of targeted novel therapeutics. He has completed a gene therapy trial using G-3039 “Bcl-antisense.” He evaluated the use of the proteosome inhibitor “bortezomib” in the newly diagnosed myeloma patients and evaluated the effects of bortezomib on stem cell. Currently, Dr. Badros is evaluating various combinations of novel therapies in multiple myeloma such as Lenalidomide and histone …deacetylase inhibitors (SAHA) in relapsed myeloma patients alone and in combinations with dexamethasone and/or bortezomib.


Dr. Ashraf Zarif Badros, MD
0
The iMedixStars rating goes beyond a simple average of reviews. It’s calculated based on various factors, including the quantity, recency, and reliability of the reviews. Read More
Overwiew
Doctor Organizations
- University Of Maryland Childrens Hospital
Doctor Education
Medical School
1985
Ain Shams University Faculty Of Medicine
Work Place
University Of Maryland And Stewart Greenebaum Comprehensive Cancer Center
22 S Greene St
Baltimore
MD
21201
USA
+14103286080
Specialties
Procedures performed
- Chemotherapy
- Chemotherapy
- Bone Marrow or Stem Cell Transplant
Insurance Plans
- Accepts Medicare
- Accepts Medicaid
- UHC Navigate HMO
- UHC Optimum Choice Preferred POS
- Aetna Select
- Aetna Signature Administrators PPO
- PHCS PPO
- UHC Choice Plus POS
- First Health PPO
- CareFirst BluePreferred PPO
- BCBS Blue Card PPO
- CareFirst BlueChoice Advantage
- Aetna Choice POS II
- CIGNA PPO
- UHC Navigate POS
- Humana Choice POS
- Aetna HMO
- CIGNA Open Access Plus
- UHC Options PPO
- Coventry Southern Health PPO
- Multiplan PPO
- CareFirst Maryland POS
- Aetna Managed Choice POS Open Access
- Humana ChoiceCare Network PPO
- Geisinger Health Plan
- CIGNA HMO
- BCBS PPO
- Aexcel PPO
- MD IPA/Optimum Choice HMO/Preferred POS
- MEDICA CHOICE WITH UNITEDHEALTHC
- UMMS Choice
- Geisinger Choice with No Referral
- UHC Nexus Open Access
- Aetna APCN Open Access Aetna Select
- Aetna Elect Choice EPO Open Access
- Aetna Open Choice PPO
- Aetna Premier Care Network APCN Choice POS II OAMC
- Aetna Small Group Maryland Elect Choice Open Access
- Aetna Small Group Maryland HMO
- BCBSA Blue Card High Performance Network
- BCBSA High Performance Network - Tiered
- CareFirst BCBS HealthBlue PPO
- CareFirst HealthyBlue HMO
- CareFirst Regional BlueChoice HMO Network
- Geisinger Marketplace All-Access PPO
- Geisinger Marketplace Extra HMO
- Geisinger Marketplace HMO
- POS
- & Value
- Humana / ChoiceCare Network PPO
- Humana/ChoiceCare+ Network PPO
- Medica Choice With UHC
- MVP Health Plan EPO/PPO
- UHC MD IPA/Optimum Choice HMO/Preferred POS
- Highmark BCBS Community Blue PPO
- Highmark BCBS my Blue Access EPO
- Highmark BCBS PPO
- Highmark BCBS PPOBlue
- CIGNA LocalPlus
- Geisinger All Access HMO
- Geisinger All Access PPO
- Highmark BCBS Community Blue Flex PPO
- Kaiser Permanente MidAtlantic
- Highmark BCBS Blue High Performance Network
- Highmark BCBS Performance Blue
- IBC Personal Choice Tiered
- Highmark BCBS MY Direct Blue EPO
Conditions
- Skin Cancer
- Malignant Neoplasm of Female Breast
- Liver Cancer
- Leukemia
- Non-Hodgkin's Lymphoma
- Multiple Myeloma
- Reviews
- Q&A
0 total
- 5 0 %
- 4 0 %
- 3 0 %
- 2 0 %
- 1 0 %
There are no questions!
Leave a comment